Jim Wassil sold $212k of PCVX
CHIEF OPERATING OFFICER at Vaxcyte, Inc.. 3,477 shares at an average of $61.07, traded Sep 1, 2026, filed Sep 2, 2026.
Score components
- +20RoleCOO
- +12Trade size$212k at market
- 0Share of holdings soldSold 2.2% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001813798-26-000017, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | FTax withholding Common Stock | -1,273 | $60.74 | $77k | 156,268 | 40 d ago |
| Sep 1, 2026 | MOption exercise Common Stock | +2,250 | $5.35 | $12k | 158,518 | 40 d ago |
| Sep 1, 2026 | SOpen-market sale Common Stock10b5-1 | -1,537 | $60.89 | $94k | 156,981 | 40 d ago |
| Sep 1, 2026 | SOpen-market sale Common Stock10b5-1 | -713 | $61.48 | $44k | 156,268 | 40 d ago |
| Sep 1, 2026 | SOpen-market sale Common Stock10b5-1 | -924 | $60.96 | $56k | 155,344 | 40 d ago |
| Sep 1, 2026 | SOpen-market sale Common Stock10b5-1 | -303 | $61.42 | $19k | 155,041 | 40 d ago |
| Sep 2, 2026 | FTax withholding Common Stock | -1,432 | $61.58 | $88k | 153,609 | 40 d ago |
| Sep 1, 2026 | MOption exercise Stock Option (right to buy)derivative | -2,250 | $0.00 | $0 | 66,648 | 40 d ago |
Related signals
Other insiders at Vaxcyte, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Vaxcyte, Inc. | Elvia Cowan SVP, Finance & CAO | $1.6M 19,000 shares | -41% | |
| 23Weak | Vaxcyte, Inc. | Jim Wassil EVP, Chief Scientific Ofc, COO | $1.6M 18,000 shares | -11% | |
| 4Weak | Vaxcyte, Inc. | Jim Wassil EVP, Chief Scientific Ofc, COO | $128k 2,250 shares | -2% | |
| 11Weak | Vaxcyte, Inc. | Jim Wassil EVP, Chief Scientific Ofc, COO | $164k 2,715 shares | -2% | |
| 5Weak | Vaxcyte, Inc. | Elvia Cowan SVP, Finance & CAO | $105k 1,892 shares | -6% | |
| 0Weak | Vaxcyte, Inc. | Elvia Cowan SVP, Finance & CAO | $146k 2,500 shares | -7% | |
| 50Moderate | Vaxcyte, Inc. | Harpreet S. Dhaliwal Chief Technical Ops Officer | $455k 9,743 shares | -29% | |
| 52Moderate | Vaxcyte, Inc. | Elvia Cowan SVP, FINANCE | $557k 11,623 shares | -44% | |
| 0Weak | Vaxcyte, Inc. | Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC | $354k 5,000 shares | -11% | |
| 15Weak | Vaxcyte, Inc. | Andrew Guggenhime PRESIDENT AND CFO | $671k 8,000 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.